High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo.
about
Novel therapeutic targets for pancreatic cancerCancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentRole of histone deacetylases in pancreas: Implications for pathogenesis and therapyAlterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical ImplicationsThe Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear StructureThe anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases modelHDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors.The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death.Chidamide Inhibits Aerobic Metabolism to Induce Pancreatic Cancer Cell Growth Arrest by Promoting Mcl-1 DegradationCurrent evidence for histone deacetylase inhibitors in pancreatic cancer.Natural chalcones as dual inhibitors of HDACs and NF-κB.Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma.Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.Targeting class I histone deacetylases in cancer therapy.Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis.HDAC inhibitors, MS-275 and salermide, potentiates the anticancer effect of EF24 in human pancreatic cancer cells.Sumoylation of HDAC2 promotes NF-κB-dependent gene expression.Reactive oxygen species, glutathione, and thioredoxin influence suberoyl bishydroxamic acid-induced apoptosis in A549 lung cancer cells.The histone deacetylase inhibitor vorinostat prevents TNFα-induced necroptosis by regulating multiple signaling pathways.HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy.Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.Deacetylase inhibitors - focus on non-histone targets and effects.Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK.Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer.Suberoylanilide hydroxamic acid induces thioredoxin1-mediated apoptosis in lung cancer cells via up-regulation of miR-129-5p.Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5.Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications.Class I histone deacetylase inhibition improves pancreatitis outcome by limiting leukocyte recruitment and acinar-to-ductal metaplasia.
P2860
Q24564267-41BA1D41-6855-4EFD-AFF8-3A7ED604BBA7Q26740619-40A94E13-7CD8-49F0-90F6-417EF573F364Q26774080-15E130BE-5D50-4097-A35D-AB4A74F6E715Q28074465-9C1DB19E-56B8-425B-B93D-BEF681E10B25Q28084785-1E56C6D6-614C-4ACE-9FDC-D7CDA85ADC99Q28533258-93D366B3-5B6E-4B2C-99B1-A68A2AAA626FQ33806343-357A9715-D308-4EC1-8404-624C73EDB8B4Q33842416-CBD91767-61F3-4FCE-AACC-9258C94ECD77Q34667550-2B74EDEB-E3AE-46E0-9C2F-A1A45D915F1CQ35133494-A1457479-BDC9-4532-94F4-4130F6E6DC25Q35183027-C54406E2-CCB0-43AE-8E6B-52C677959D67Q36201181-1602C9F0-11A5-4E62-8A4D-0D4D371DF1FBQ36616790-DD7CFC57-90E7-40F4-9BDF-901425CFE6C1Q36642705-E041B581-B8D3-49BE-9618-A16F81E9D8F6Q37832684-4224AAE0-1CB6-43A9-986D-C0B82BCDEF2AQ38012499-6C6E0BC4-4089-4E7E-82A5-582416081EF2Q38016227-EC62456A-4C05-4921-BD01-2FB11C4EDB40Q38051736-2B22C5DE-7C9E-4F38-97FF-5CB77FA843D7Q38052795-89B150C2-9826-409A-AC41-544363B23ACBQ38762886-0EEDB3A4-95A4-4C8D-BBBB-7E5D96DE51C9Q38907048-62FB8655-1E1D-4E91-BA11-EFEE4B9B32EFQ38925745-1FED0527-496A-4FA8-95BF-A1E9253C3CBDQ39147238-C1F9FDCF-C856-4057-9625-C6A9A9520C2AQ39307665-89D220E1-7A7C-4EAC-93F2-8292B5373B48Q40971366-C1523ACB-2A88-4322-821D-C51D3EF3BFE9Q41120940-9FD6C4CF-9A2A-46EC-A51D-FA9C7CE9BD05Q41808915-D02E7BAE-CA9E-41CB-A121-FB2EF1BF6B54Q42248631-0DEFF964-B9F9-4880-8BBA-6B326C43E6DEQ42362715-3727697E-871B-4385-9D41-AD18A9BC0E3BQ46341905-7AFA7CE5-79E8-456F-AE92-D4AA1C5A2274Q47113094-5F736811-6669-4E1B-9BD7-223813D741A8Q47912546-E032E8C3-0924-43DE-99B0-6D5F027D24A6Q48194888-4910026D-CA9F-46F4-89C0-433C2E7A8E0D
P2860
High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
High class I HDAC activity and ...... c cancer in vitro and in vivo.
@ast
High class I HDAC activity and ...... c cancer in vitro and in vivo.
@en
type
label
High class I HDAC activity and ...... c cancer in vitro and in vivo.
@ast
High class I HDAC activity and ...... c cancer in vitro and in vivo.
@en
prefLabel
High class I HDAC activity and ...... c cancer in vitro and in vivo.
@ast
High class I HDAC activity and ...... c cancer in vitro and in vivo.
@en
P2093
P2860
P50
P356
P1433
P1476
High class I HDAC activity and ...... c cancer in vitro and in vivo.
@en
P2093
Annika Lehmann
Carsten Denkert
Glen Kristiansen
Jan Budczies
Marcus Bahra
P2860
P2888
P356
10.1186/1471-2407-9-395
P407
P50
P577
2009-11-13T00:00:00Z
P5875
P6179
1012436249